Articles by Asensio.com

No officer, director, employee or agent of Asensio & Company, Inc. (“Asensio”) has any relationship with Finkelstein, Thompson, & Loughran (“FTL”). Hemispherx’s release alleging a relationship between Asensio and FTL is completely false and untrue. […]

The Food and Drug Administration (“FDA”) authorized Hemispherx Biopharma, Inc.’s (AMEX symbols: HEB and HEBWS) (Price: $7.00) (“HEB”) Ampligen CFS Phase III clinical trials on October 9, 1992. This means that Hemispherx’s approval to conduct […]

The following Ampligen Safety Profile has been copied directly from pages 43 and 44 of Hemispherx Biopharma, Inc.’s (“Hemispherx”) Initial Public Offering Prospectus dated November 2, 1995 (“Prospectus”). This description contains both Hemispherx’s characterization of […]

Hemispherx Biophrama, Inc.’s (AMEX Symbol: HEB) (Price: $8.875) presented 7 year old Ampligen data at the American Association for Chronic Fatigue Syndrome’s (“AACFS”) Fourth International CFS conference held in Boston this weekend. The conference Chairman […]

On July 29, 1998 The Oprah Winfrey Show aired a show titled “Diseases Doctors Miss Most.” This show contained a brief segment that discussed Chronic Fatigue Syndrome (“CFS”). There was no mention of Hemispherx Biopharma, […]

On September 23, 1998, Dr. William A. Carter, Chairman of Hemispherx Biopharma, Inc., (AMEX symbols: HEB and HEBWS) (Price: $6.00) hosted a conference call. Dr. Carter devoted a large portion of this call to an […]

Asensio & Company, Inc. (“Asensio”) denies that it had or has ever had any co-conspirators and denies knowledge of or participation in a scheme by short-sellers to manipulate Hemispherx’s stock price and defraud Hemispherx investors. […]

Hemispherx Biopharma, Inc. (AMEX symbols: HEB and HEBWS) (Price: $6.00) has misrepresented Ampligen’s clinical trial results and its Food and Drug Administration (“FDA”) filing and approval status. In a letter dated September 30, 1998, Asensio […]

Hemispherx Biopharma, Inc. (AMEX symbols: HEB and HEBWS) (Price: $5.875) issued a press release on September 29, 1998. The release concerned the incidence of Chronic Fatigue Syndrome (“CFS”) and cited a Harvard study “led by […]

Hemispherx Biopharma, Inc. (AMEX: HEB and HEBWS) (Price: $5.875) was sued by one of its private investors for its actions in preventing the conversion of 1,500 shares of Series E Convertible Preferred Stock (“Convertible Preferred”) […]

Yesterday, Hemispherx Biopharma, Inc. (AMEX: HEB and HEBWS) (Price: $5.875) issued a statement claiming that a study from Harvard University School of Medicine led by Dr. Anthony Komaroff states “that up to 2 million Americans […]

On Monday, September 21, 1998, Hemispherx Biopharma, Inc. (AMEX symbols: HEB and HEBWS) (Price: $6.375) announced that it had “signed a letter of intent to acquire a significant equity stake in California Institute of Molecular […]

Asensio & Company, Inc. initiates coverage of Hemispherx Biopharma, Inc. (AMEX Symbol: HEB and HEB/WS) (Price: $8.00) with a Strong Sell and Short Sell recommendation. Investors may be buying shares of Hemispherx believing that the […]

Asensio & Company, Inc. has issued a ten page institutional research report and Strong Sell recommendation on Hemispherx Biopharma, Inc. (AMEX symbols: HEB and HEBWS) (Price: $8.00). The document begins with Asensio & Company’s summary […]

Manuel P. Asensio (212) 702-8805 HEMISPHERx BIOPHARMA, INC. (AMEX Symbols: HEB and HEB/WS)(1) Closing Price: $8 Book Value Per Share:(5) $0.36 52-Week Trading Range: $13 3/16 – 2 5/8 Aggregate Market Value: $321 million Shares […]